Cellular characterisation of p53 mutants with a single missense mutation in the β-strand 326-333 and correlation of their cellular activities with in vitro properties

Journal of Molecular Biology

Volumn 288, Issue 5, 1999, Pages 891-897

  Chène, Patrick ^a   Bechter, Elisabeth ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Beta strand; Oligomerisation; p53; Tetramerisation

Indexed keywords

ALANINE; ARGININE; GLUTAMIC ACID; GLUTAMINE; ISOLEUCINE; LEUCINE; MUTANT PROTEIN; PHENYLALANINE; PROTEIN P53; THREONINE; TYROSINE;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; CELL ACTIVITY; CELL GROWTH; CONTROLLED STUDY; MISSENSE MUTATION; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DOMAIN; PROTEIN SECONDARY STRUCTURE; PROTEIN STABILITY; THERMODYNAMICS; TRANSCRIPTION INITIATION;

ANIMALIA;

EID: 2542509342     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmbi.1999.2738     Document Type: Article

References (34)

1. Caelle C., Helmberg A., Karin M. p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature. 370:1994;220-223.
2. Chène P., Mittl P., Grutter M. In vitro structure-function analysis of the β-strand 326-333 of human p53. J. Mol. Biol. 273:1997;873-881.
3. Chin K. V., Ueda K., Pastan I., Gottesman M. M. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science. 255:1992;459-462.
4. Clore G. M., Omichinski J. G., Sakaguchi K., Zambrano N., Sakamoto H., Appella E., Grenenborn A. M. High-resolution structure of the oligomerization domain of p53 by multidimensional NMR. Science. 265:1994;386-391.
5. Davison T. S., Yin P., Nie E., Kay C., Arrowsmith C. H. Characterization of the oligomerization defects of two p53 mutants found in families with Li-Fraumeni and Li-Fraumeni-like syndrome. Oncogene. 17:1998;651-656.
6. Diller L., Kassel J., Nelson C. E., Gryka M. A., Litwak G., Gebhardt M., Bressac B., Ozturk M., Baker S., Vogelstein B., Friend S. H. p53 functions as a cell cycle control protein in osteosarcomas. Mol. Cell. Biol. 10:1990;5772-5781.
7. Dittmer D., Pati S., Zambetti G., Chu S., Teresky A. K., Moore M., Finaly C., Levine A. J. Gain of function mutations in p53. Nature Genet. 4:1993;42-46.
8. El-Deiry W. S., Tokino T., Velculescu V. E., Levy D. B., Parsons R., Trent J. M., Lin D., Mercer W. E., Kinzler K. W., Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell. 75:1993;817-825.
9. Graeber T. G., Peterson J. F., Tsai M., Monica K., Fornace A. J. Jr, Giaccia A. J. Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status. Mol. Cell. Biol. 14:1994;6264-6277.
10. Hollstein M., Sidransky D., Vogelstein B., Harris C. C. p53 mutations in human cancers. Science. 264:1991;1317-1319.
11. Ishioka C., Englert C., Winge P., Yan Y. X., Engelstein M., Friend S. H. Mutational analysis of the carboxy-terminal portion of p53 using both yeast and mammalian cell assays in vivo. Oncogene. 10:1995;1485-1492.
12. Ishioka C., Shimodaira H., Englert C., Shimada A., Osada M., Jia L. Q., Suzuki T., Gamo M., Kanamuru R. Oligomerization is not essential for growth suppression by p53 in p53-deficient osteosarcoma Saos-2 cells. Biochem. Biophys. Res. Commun. 232:1997;54-60.
13. Jeffrey P. D., Gorina S., Pavletich N. Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science. 267:1995;1498-1502.
14. Kastan M. B., Onyekwere O., Sidransky D., Vogelstein B., Craig R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51:1991;6304-6311.
15. Kirsch D. G., Kastan M. B. Tumor-suppressor p53: implications for tumor development and prognosis. J. Clin. Oncol. 16:1998;3158-3168.
16. Ko. L. J., Prives C. p53: puzzle and paradigm. Genes Dev. 10:1996;1054-1072.
17. Lányi A., Deb D., Seymour R. C., Ludes-Meyers J. H., Subler M. A., Deb S. 'Gain of function' phenotype of tumor-derived mutant p53 derives the oligomerization/nonsequence-specific nucleic acid-binding domain. Oncogene. 16:1998;3169-3176.
18. Lee W., Harvey T. S., Yin Y., Yau P., Litchfield D., Arrowsmith C. H. Solution structure of the tetrameric minimum transforming domain of p53. Nature Struct. Biol. 1:1994;877-890.
19. Levine A. J. p53, the cellular gatekeeper for growth and division. Cell. 88:1997;323-331.
20. Levine A. J., Wu M. C., Chang A., Silver A., Attiyeh E. F., Lin J., Epstein C. B. The spectrum of mutations at the p53 locus. Ann. N.Y. Acad. Sci. 768:1995;111-128.
21. Lin J., Chen J., Elenbaas B., Levine A. J. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5E1B-55-kD protein. Genes Dev. 8:1994;1235-1346.
22. Linke S. P., Clarkin K. C., DiLeonardo A., Tsou A., Wahl G. M. A reversible, p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. Genes Dev. 10:1996;934-947.
23. Liu F. S., Kohler M. F., Marks J. R., Bast R. C., Boyd J., Berchuck A. Mutation and overexpression of the p53 tumor suppressor gene frequently occurs in uterine and ovarian sarcomas. Obstet. Gynecol. 83:1994;118-124.
24. Lomax M. E., Barnes D. M., Gilchrist R., Picksley S. M., Varley J. M., Camplejohn R. S. Two functional assays employed to detect an unusual mutation in the oligomerisation domain of p53 in a Li-Fraumeni like family. Oncogene. 14:1997;1869-1874.
25. Lomax M. E., Barnes D. M., Hupp T. R., Picksley S. M., Camplejohn R. S. Characterization of p53 oligomerization domain mutations isolated from Li-Fraumeni and Li-Fraumeni like family members. Oncogene. 17:1998;643-649.
26. Mateu M. G., Fersht A. R. Nine hydrophobic side chains are key determinants of the thermodynamic stability and oligomerization status of tumour suppressor p53 tetramerization domain. EMBO J. 17:1998;2748-2755.
27. Miyashita T., Reed J. C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 80:1995;293-299.
28. Ng I. O. L., Chung L. P., Tsang S. W. Y., Lam E. C. S., Fan S. T., Ng M. p53 gene mutation spectrum in hepatocellular carcinomas in Hong Kong Chinese. Oncogene. 9:1994;985-990.
29. Pavletich N. P., Chambers K. A., Pabo C. O. The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. Genes Dev. 7:1993;2556-2564.
30. Rollenhagen C., Chène P. Characterization of p53 mutants identified in human tumors with a missense mutation in the tetramerization domain. Int. J. Cancer. 1998;372-376.
31. Soussi T., May P. Structural aspects of the p53 protein in relation to gene evolution: a second look. J. Mol. Biol. 260:1996;623-637.
32. Strauss B. E., Haas M. The region 3′ to the major transcriptional start site of the MDR1 downstream promoter mediates activation by a subset of mutant p53 proteins. Biochim. Biophys. Res. Commun. 217:1995;333-340.
33. Subler M. A., Martin D. W., Deb S. Overlapping domains on the p53 protein regulate its transcriptional activation and repression functions. Oncogene. 9:1994;1351-1359.
34. Waterman J. L., Shenk J. L., Halazonetis T. D. The dihedral symmetry of the p53 tetramerization domain mandates a conformational switch upon DNA binding. EMBO J. 14:1995;512-519.